Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 3Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Endocrine 1

Conditions

Carcinoma, Neuroendocrine 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 1492Cisplatin 1415Paclitaxel 1319Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1111Bevacizumab 1031Fluorouracil 895Doxorubicin 792Dexamethasone 748Rituximab 720Capecitabine 717Oxaliplatin 701pembrolizumab 680Etoposide 678Irinotecan 636Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 560Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 428Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × TLC 388 × Clear all
NCT00747474 2019-11-18

Phase I Study of Intravenous LipotecanĀ® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors

Taiwan Liposome Company

Phase 1 Completed
54 enrolled 30 charts
Other solid neoplasm

Advanced Solid Tumors

NCT02457273 2019-04-03

Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients

National Health Research Institutes, Taiwan

Phase 2 Completed
23 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚔